Jump to main content
Jump to site search


Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed dose combination antituberculosis pharmaceutical formulations: a review

Abstract

According to the World Health Organization, rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride are the first line drugs used to treat tuberculosis, an infectious disease caused by Mycobacterium tuberculosis. Since 2010, tuberculosis disease has been treated with fixed dose combination containing the four drugs in only one tablet, called 4-FDC, which simplified the treatment, minimizing prescription errors and increasing the patients’ adherence. Within this context, the present review has the aim to show the evolution of different analytical methods applied to simultaneous 4-FDC content determination in pharmaceutical formulations, employing high performance liquid chromatography, ultra-high performance liquid chromatography, thin layer chromatography and capillary electrophoresis as separation techniques and techniques of molecular spectroscopies associated to chemometric approaches such as UV, Raman, Fourier-transform infrared and near infrared.

Back to tab navigation

Publication details

The article was received on 20 Nov 2017, accepted on 08 Feb 2018 and first published on 12 Feb 2018


Article type: Critical Review
DOI: 10.1039/C7AY02686B
Citation: Anal. Methods, 2018, Accepted Manuscript
  •   Request permissions

    Simultaneous determination of rifampicin, isoniazid, pyrazinamide and ethambutol in fixed dose combination antituberculosis pharmaceutical formulations: a review

    M. A. L. de Oliveira, P. Chellini and T. L. Amorim, Anal. Methods, 2018, Accepted Manuscript , DOI: 10.1039/C7AY02686B

Search articles by author

Spotlight

Advertisements